Starpharma Holdings Ltd Announce New Indication for VivaGel(R): Bacterial Vaginosis

July 9, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Melbourne, July 9, 2008 (ABN Newswire) - Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced that it will add the treatment of bacterial vaginosis (BV) to the development program for its vaginal microbicide VivaGel(R).

Twitter
LinkedIn
Facebook
Email
Print

Europe Australia